Samsung Biologics Co.,Ltd.'s latest marketcap:
As of 07/19/2026, Samsung Biologics Co.,Ltd.'s market capitalization has reached $43.45 B. According to our data, Samsung Biologics Co.,Ltd. is the 579th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 43.45 B |
| Revenue (ttm) | 3.24 B |
| Net Income (ttm) | 1.26 B |
| Shares Out | 46.29 M |
| EPS (ttm) | 18.85 |
| Forward PE | 32.27 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/23/2026 |
Samsung Biologics Co.,Ltd.'s yearly market capitalization.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/19/2026 | ₩64.62 T | $43.45 B | -23.6% | 579 |
| 12/30/2025 | ₩78.46 T | $53.32 B | 16.17% | 398 |
| 12/30/2024 | ₩67.54 T | $45.25 B | 24.87% | 418 |
| 12/28/2023 | ₩54.09 T | $41.65 B | -7.43% | 426 |
| 12/29/2022 | ₩58.43 T | $46.16 B | -2.2% | 333 |
| 12/30/2021 | ₩59.75 T | $50.19 B | 9.32% | 380 |
| 12/30/2020 | ₩54.65 T | $0 | 90.76% | 312 |
| 12/30/2019 | ₩28.65 T | $24.64 B | 12.03% | 571 |
| 12/28/2018 | ₩25.57 T | $22.76 B | 4.18% | 503 |
| 12/28/2017 | ₩24.55 T | $22.83 B | 145.7% | 571 |
Company Profile
About Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd., along with its subsidiaries, specializes in the manufacturing of biopharmaceutical products. Headquartered in Incheon, South Korea, the company operates globally, serving markets in Europe, the United States, and beyond.
Business Segments
- Contract Development and Manufacturing Organization (CDMO): Provides end-to-end biopharmaceutical manufacturing solutions.
- Biopharmaceutical Development and Commercialization: Focuses on biosimilar drugs, antibody-drug conjugates, and mRNA products.
Key Services
- Development Services: Late discovery, cell line development, process development, analytical development, and non-GMP/CGMP manufacturing.
- Manufacturing & Support: Aseptic filling, lyophilization, finishing, storage, shipping, and regulatory support.
- Quality & Testing: Biosafety testing, analytical testing, and drug substance manufacturing.
Founded in 2011, Samsung Biologics has established itself as a leader in the biopharmaceutical industry, delivering innovative and high-quality solutions.
Frequently Asked Questions
-
What is Samsung Biologics Co.,Ltd.'s (KRX-207940) current market cap?As of 07/19/2026, Samsung Biologics Co.,Ltd. (including the parent company, if applicable) has an estimated market capitalization of $43.45 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Samsung Biologics Co.,Ltd. (KRX-207940) rank globally by market cap?Samsung Biologics Co.,Ltd. global market capitalization ranking is approximately 579 as of 07/19/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.